Showing 1 - 10 of 301
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
We propose an empirical strategy for estimating competition in innovation markets based on a model of creative-destruction. Our method relates firms’ market return on equity to information about patent citation patterns. Two innovations we introduce are using daily abnormal stock returns...
Persistent link: https://www.econbiz.de/10014204193
How does a firm’s market power in existing products affect its incentives to innovate? We explore this fundamental question using granular project-level and firm-level data from the pharmaceutical industry, focusing on a particular mechanism through which incumbent firms maintain their market...
Persistent link: https://www.econbiz.de/10012818283
In 1996, the chemical firm Monsanto bought a plant breeder that had developed a new corn hybrid, which could withstand Monsanto’s powerful herbicide Roundup. Due to the pre-existing structure of the US plant-breeding industry, this acquisition and Monsanto’s acquisition of five other corn...
Persistent link: https://www.econbiz.de/10014136711
This paper studies how competition impacts innovative firms’ voluntary disclosure of product quality information. Our empirical context is the pharmaceutical industry, where firms must decide whether to disclose drug quality information acquired in clinical trials. Leveraging variation in...
Persistent link: https://www.econbiz.de/10013290248
3D printing is a new manufacturing method used to make customized products that is also instrumental in driving manufacturing innovation. The global market for this technology has expanded rapidly thanks to a sharp increase in industrial applications. However growth of the Korean 3D printing...
Persistent link: https://www.econbiz.de/10014263159
As finding breakthrough small-molecule drugs gets harder, drug companies are increasingly turning to “large molecule” biologics. Although biologics represent many of the most promising new therapies for previously intractable diseases, they are extremely expensive. Moreover, the pathway for...
Persistent link: https://www.econbiz.de/10013219143
This study analyses the incentives for process innovations under different conditions determined by the competition policy for intellectual property rights (IPR) and particular features of markets and technologies. Competition policy is defined by the presence or absence of compulsory licensing,...
Persistent link: https://www.econbiz.de/10013024356
We examine the impact of product market competition on innovation in markets for technology. An innovator makes an investment in quality-improving innovation that can be licensed to one (targeted licensing) or all (market-wide licensing) product market competitors. Our model points to a U-shaped...
Persistent link: https://www.econbiz.de/10013213274
The study is an exploratory study on the state of exports within the Ghanaian pharmaceutical manufacturing industry. Data was obtained from interviews of key managers involved in strategy formulation of 5 exporting pharmaceutical manufacturing companies in Ghana. The study revealed that out of...
Persistent link: https://www.econbiz.de/10011205838